Motif Bio Conference Call and Webcast
https://www.motifbio.com/wp-content/uploads/2019/02/MTFB-Conf-call-RNS-19.02.19.pdf
Motif BioSciences Enters into Amendment Agreement with Hercules Capital
https://www.motifbio.com/wp-content/uploads/2019/02/20190218_PR-MTFB-Hercules-amendment_FINAL-UPDATED.pdf
Holding(s) in Company
https://www.motifbio.com/wp-content/uploads/2019/02/MTFB-TR-1-Prudential-plc-group-of-companies-15.02.19.pdf
Holding(s) in Company
https://www.motifbio.com/wp-content/uploads/2019/02/MTFB-TR-1-Invesco-Ltd.-15.02.19.pdf
Motif Bio Receives Complete Response Letter from the FDA
https://www.motifbio.com/wp-content/uploads/2019/02/MTFB-PDUFA-decision-PR-14.02.19.pdf
Exercise of Warrants
https://www.motifbio.com/wp-content/uploads/2019/02/MTFB-Exercise-of-Warrants-05.02.19-1.pdf
Exercise of Warrants
https://www.motifbio.com/wp-content/uploads/2019/01/RNS-Warrant-North.-Rock-1.23.19.pdf
Motif Bio to participate at upcoming Jefferies London Healthcare Conference
https://www.motifbio.com/wp-content/uploads/2018/10/20181031_MTFB_Jefferies-London-conf-curtain-raiser-PR.pdf
Motif Bio Presents New Iclaprim Data at IDWeek
https://www.motifbio.com/wp-content/uploads/2018/10/20181003_IDWeek-2018-data-PR.pdf
Motif Bio Notes Statement from Amphion Innovations
https://www.motifbio.com/wp-content/uploads/2018/09/MTFB-AMP-statement-28.09.18.pdf
Motif Bio Reports Half-Year 2018 Financial Results and Operational Progress
https://www.motifbio.com/wp-content/uploads/2018/09/6.30.18-MTFB-Interim-Results-Final.pdf
Motif Bio to Present Iclaprim Data at Upcoming Scientific Conferences
https://www.motifbio.com/wp-content/uploads/2018/09/20180920_IDWeek_World-AMR-Congress-2018-curtain-raiser-PR.pdf
Motif Bio Presents Iclaprim Data at ESCMID/ASM Conference
https://www.motifbio.com/wp-content/uploads/2018/09/20180905_ESCMID_ASM-2018-data-PR.pdf
Motif Bio notes statement from Amphion Innovations
https://www.motifbio.com/wp-content/uploads/2018/08/MTFB-notes-AMP-statement-21.08.18.pdf
Motif Bio to Present Iclaprim Data at ESCMID/ASM Conference
https://www.motifbio.com/wp-content/uploads/2018/08/20180817_ESCMID_ASM-2018-curtain-raiser-PR_.pdf
Holding(s) in Company
https://www.motifbio.com/wp-content/uploads/2018/08/Motif-Bio-PLC-TR1-14082018.pdf
Holding(s) in Company
https://www.motifbio.com/wp-content/uploads/2018/08/tr-1-form-NEW-MotifBio-20180813-company-NEW-003.pdf
Motif Bio Announces FDA Acceptance of New Drug Application with Priority Review for Iclaprim for Treatment of Acute Bacterial Skin and Skin Structure Infections
https://www.motifbio.com/wp-content/uploads/2018/08/MTFB-FDA-acceptance-of-NDA-14.08.18-1.pdf
Motif Bio to Present at Investor Events in August and September
https://www.motifbio.com/wp-content/uploads/2018/08/20180809_MTFB_Late-Summer-Investor-Events-2018_PR.pdf
Motif Bio Announces Notice of Allowance for Two U.S. Iclaprim Patents with Expiration in 2037
https://www.motifbio.com/wp-content/uploads/2018/08/20180808_MTFB_Notices-of-allowance-PR.pdf
Motif Bio Announces Resignation of Robert Bertoldi from Board of Directors
https://www.motifbio.com/wp-content/uploads/2018/07/20180703_MTFB_BoD-resignation.pdf
Holding(s) in Company
https://www.motifbio.com/wp-content/uploads/2018/07/Motif-Bio-PLC-TR1-For-29-June-2018-Issuer.pdf
Exercise of Stock Options
https://www.motifbio.com/wp-content/uploads/2018/06/2018-6-26-RNS-Option-Exercise-Stakes.pdf
Result of Annual General Meeting
https://www.motifbio.com/wp-content/uploads/2018/06/MTFB-Result-of-AGM-19.06.18.pdf
Motif Bio Submits NDA for Iclaprim
https://www.motifbio.com/wp-content/uploads/2018/06/20180614_Submission-of-Iclaprim-ABSSSI-NDA_MTFB_PR.pdf
Holding(s) in Company
https://www.motifbio.com/wp-content/uploads/2018/06/MTFB-TR-1-HSBC-11.06.18.pdf
Motif Bio Announces New Iclaprim Data Presented at ASM Microbe 2018
https://www.motifbio.com/wp-content/uploads/2018/06/20180611_ASM-Pooled-REVIVE-data_MTFB-PR.pdf
Holding(s) in Company
https://www.motifbio.com/wp-content/uploads/2018/06/06.06.2018-Motif-Bio-Plc-Issuer.pdf
Motif Bio to present at Jefferies Global Healthcare Conference in New York
https://www.motifbio.com/wp-content/uploads/2018/05/20180531_MTFB-Jefferies-conference-PR.pdf
Holding(s) in Company
https://www.motifbio.com/wp-content/uploads/2018/05/MTFB-TR-1-American-Corporation-25.05.18.pdf
Holding(s) in Company
https://www.motifbio.com/wp-content/uploads/2018/05/tr-1-form-NEW-MotifBio-20180523-company-NEW.pdf
Holding(s) in Company
https://www.motifbio.com/wp-content/uploads/2018/05/MTFB-TR-1-SAND-GROVE-CAPITAL-MANAGEMENT-LLP23.05.18.pdf
Motif Bio notes statement from Amphion Innovations
https://www.motifbio.com/wp-content/uploads/2018/05/MTFB-AMP-Holdings-in-Company-23.05.18.pdf
Result of Placing
https://www.motifbio.com/country-select-2018/
Proposed Placing to raise approximately £10m
https://www.motifbio.com/country-select-2018/
Motif Bio Appoints Stephanie Noviello, MD, MPH as Vice President, Clinical Development
https://www.motifbio.com/wp-content/uploads/2018/05/20180509_MTFB_VP-Clin-Dev_PR.pdf
Motif Bio to Present Iclaprim Data at ASM Microbe 2018
https://www.motifbio.com/wp-content/uploads/2018/05/20180508_MTFB_ASM-Curtain-raiser.pdf
Motif Bio REVIVE-2 Phase 3 Study Results with Iclaprim Published in Peer-reviewed Journal, Antimicrobial Agents and Chemotherapy
https://www.motifbio.com/wp-content/uploads/2018/04/20180501_MTFB_REVIVE-2-publication-PR.pdf
Motif Bio Announces New Iclaprim Data being Presented at ECCMID 2018
https://www.motifbio.com/wp-content/uploads/2018/04/MTFB_ECCMID-data-PR-Final-19.04.18.pdf
Posting of UK Annual Report and Accounts & Notice of AGM
https://www.motifbio.com/wp-content/uploads/2018/04/MTFB-Posting-of-UK-Annual-Report-and-Accounts-Notice-of-AGM-17.04.18-1.pdf
This website uses cookies to improve your experience. You can opt-out if you wish.
Accept Read More Privacy & Cookies Policy
